No­vavax says its Covid-19 vac­cine proved 89.3% ef­fec­tive in UK tri­al in­clud­ing vari­ant — while South African re­sults slide low­er

Af­ter play­ing be­hind for much of the Covid-19 vac­cine race, No­vavax has come along with the first ef­fi­ca­cy for its pro­tein-based shot, in­clud­ing one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.